



This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds of the formula I



in which

X = N or CH,

R¹, R², R³ = independently of one another OH, OA, CN, Hal, COR⁴ or CH₂R⁴,

R⁴ = OH, OA, NH₂, NHB or NB₂,

Q = CH₂ or CO,

A, B = independently of one another straight-chain or branched alkyl or alkoxy

having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms or alkoxyalkyl having 2 to 10 C atoms,
m = 2, 3, 4, 5 or 6 and
n = 0, 1, 2, 3 or 4,
or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.

2. (Previously Presented) Compounds according to Claim 1 in which

X = N,

R¹, R², R³ = independently of one another CN, OH, COR⁴ or CH₂R⁴,

R⁴ = OH, NH₂, NHB or NHB₂,

Q = CH₂ or CO,

B = alkyl having 1-6 C atoms,


m = 4 and

n = 0,

or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.


3. (Previously Presented) A compound according to Claim 1 which is

- a) 5-{4-[4-(5-cyano-2,3-dihydro-1H-indol-3-yl)butyl]piperazin-1-yl}benzofuran-2-carboxamide




or

- b) 5-{4-[4-(5-cyano-2-oxo-2,3-dihydro-1H-indol-3-yl)butyl]piperazin-1-yl}-benzofuran-2-carboxamide



4. (Currently Amended) Process for the preparation of compounds according to claim 1 or physiologically acceptable salts or stereoisomers thereof, comprising


- a) reacting a compound of the formula II, in which R^1 , R^2 , R^3 , X, m and n have the meanings indicated in Claim 1,




with dimethyl sulfoxide and concentrated HCl,

or

- b) reacting a compound of the formula III, in which R^1 , R^2 , and n have the meanings indicated in Claim 1, and Y is a halogen or an alcohol provided with protecting groups,




with trifluoroacetic acid and triethylsilane and subsequently coupling with a compound of the formula IV, in which R³, X and n have the meanings indicated in Claim 1



and reacting with dimethyl sulfoxide and concentrated HCl

or

- c) reacting a compound of the formula V, in which R² and m have the meanings indicated in Claim 1 and Y is a halogen, or an alcohol provided with protecting groups,



with a dehydrating reagent and subsequently coupling with a compound of the formula IV, and reacting with dimethyl sulfoxide and concentrated HCl.

5. (Cancelled)
6. (Previously Presented) Pharmaceutical composition comprising at least one compound according to claim 1 and/or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios, and a pharmaceutically acceptable carrier.
7. (Previously Presented) Pharmaceutical composition, according to Claim 6 comprising further excipients and/or adjuvants.
8. (Canceled).
9. (Currently Amended) Process for the preparation of a pharmaceutical composition, comprising bringing a compound according to claim 1 and/or one of its physiologically acceptable salts, ~~solvates~~ or stereoisomers, including mixtures thereof in all ratios, into a suitable dosage form together with a solid, liquid or semi-liquid excipient or adjuvant.
10. (Cancelled)
11. (Cancelled)
12. (Currently Amended) A method of achieving an anxiolytic, antidepressant, neuroleptic and/or antihypertonic effect ~~and/or and for treatment and/or prevention of treating~~ migraine, cerebral infarctions or obsessive compulsive disorder,

comprising administering to a host in need thereof an effective amount of a compound according to claim 1 and/or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.

13. (Cancelled)

14. (Canceled).

15. (Previously Presented) A method for the treatment of stroke or cerebral ischaemia, comprising administering to a host in need thereof an effective amount of a compound according to claim 1 and/or physiologically acceptable salts or stereoisomers thereof, including mixtures thereof in all ratios.